C78.0

Secondary malignant neoplasm of lung

Secondary malignant neoplasm of the lung, also known as pulmonary metastasis, refers to the development of cancerous tumors in the lung tissue that originated from a primary malignancy located in another organ. The lungs are among the most common sites for metastatic spread due to their extensive microvasculature and the fact that they receive the entire cardiac output through the pulmonary circulation. Cancer cells detach from a primary tumor, travel through the bloodstream (hematogenous spread) or the lymphatic system, and eventually lodge in the small capillaries of the lungs where they proliferate into secondary tumors. Clinically, these metastases often present as multiple bilateral nodules, although solitary pulmonary nodules can occur. While some patients remain asymptomatic, others develop respiratory symptoms such as cough or dyspnea. The diagnosis is frequently established via chest radiography or computed tomography (CT) as part of routine staging or surveillance for a known primary cancer. Management is complex and primarily directed toward the underlying primary disease using systemic therapies like chemotherapy, immunotherapy, or targeted therapy, though local interventions such as surgical resection or ablation may be considered for certain patients with limited metastatic burden.

Clinical Symptoms

Persistent, non-productive or productive cough
Dyspnea on exertion or at rest
Hemoptysis (coughing up blood)
Pleuritic chest pain
Unexplained weight loss and anorexia
Generalized fatigue
Hoarseness (due to recurrent laryngeal nerve involvement)
Wheezing or stridor from airway obstruction
Pleural effusion causing lung compression
Fever of unknown origin

Common Causes

Metastasis from breast carcinoma
Metastasis from colorectal adenocarcinoma
Metastasis from renal cell carcinoma
Metastasis from malignant melanoma
Metastasis from primary bone or soft tissue sarcomas
Metastasis from thyroid carcinoma
Metastasis from bladder or prostate cancer
Metastasis from uterine or ovarian cancer
Metastasis from head and neck squamous cell carcinoma
Lymphangitic spread from abdominal or thoracic malignancies

Documentation & Coding Tips

Clearly differentiate the lung as a secondary site from a primary lung malignancy.

Example: Note: Patient with a history of sigmoid colon cancer presents with new pulmonary nodules. Biopsy of the right lower lobe nodule confirms metastatic adenocarcinoma of colonic origin. Assessment: Secondary malignant neoplasm of the right lung. Billing Focus: Selection of C78.01 (Right lung) over C34.11 (Primary right upper lobe) is critical for medical necessity and accurate site reporting. Risk Adjustment: Documentation of metastatic status (Secondary) triggers HCC 8, representing high clinical complexity.

Billing Focus: Identification of the lung as a secondary rather than primary site using the C78.0 series.

Specify the laterality of the lung involvement to the highest degree of specificity.

Example: Note: Follow-up for patient with metastatic renal cell carcinoma. Recent CT imaging demonstrates multiple bilateral pulmonary nodules consistent with metastatic spread. Assessment: Secondary malignant neoplasm of the right lung and secondary malignant neoplasm of the left lung. Billing Focus: Coding both C78.01 and C78.02 is necessary when both lungs are involved to reflect the full extent of the disease. Risk Adjustment: Bilateral involvement underscores the severity of the metastatic burden.

Billing Focus: Use of specific laterality codes C78.01 for right and C78.02 for left lung instead of the unspecified C78.00.

Document the relationship between the lung metastasis and the primary site, including whether the primary site is active or history of.

Example: Note: Patient with history of invasive ductal carcinoma of the right breast, status post mastectomy three years ago. Presenting with new cough and C78.01 confirmed by CT-guided biopsy. Assessment: Secondary malignant neoplasm of the right lung. Billing Focus: Code C78.01 as the primary diagnosis and Z85.3 (Personal history of malignant neoplasm of breast) as a secondary diagnosis if the primary breast cancer is no longer under active treatment. Risk Adjustment: Capturing both the history of the primary and the active secondary neoplasm ensures accurate longitudinal risk scoring.

Billing Focus: Correct sequencing of the metastatic site code and the primary site code or history-of code.

Include associated complications such as pleural effusion or lymphadenopathy in the documentation.

Example: Note: Patient with known metastatic melanoma to the lung presents with increasing shortness of breath. Ultrasound confirms a large malignant pleural effusion. Assessment: Secondary malignant neoplasm of unspecified lung with malignant pleural effusion. Billing Focus: Reporting both C78.00 and J91.0 (Malignant pleural effusion) captures the complexity of the patient's presentation. Risk Adjustment: The addition of malignant pleural effusion increases the intensity of care required and supports a higher level of medical decision making.

Billing Focus: Coding secondary manifestations like pleural effusion (J91.0) alongside the metastatic site (C78.0).

Document the specific lobe or region of the lung when possible, even if the ICD-10 code is limited to laterality.

Example: Note: Patient with metastatic prostate cancer shows a single enlarging nodule in the right middle lobe. Plan for stereotactic body radiation therapy. Assessment: Secondary malignant neoplasm of the right lung, specifically the right middle lobe. Billing Focus: Specific lobe documentation supports the medical necessity of localized procedures like radiation or wedge resection. Risk Adjustment: Precise anatomical documentation facilitates better clinical outcomes tracking for metastatic lesions.

Billing Focus: Anatomical specificity beyond the code title to support procedural medical necessity.

Relevant CPT Codes

99214 - Office or other outpatient visit for the evaluation and management of an established patient, which requires a moderate level of medical decision making and 30-39 minutes of total time spent on the date of the encounter
Typically used for monthly oncology follow-ups to evaluate response to treatment in patients with metastatic disease.
99215 - Office or other outpatient visit for the evaluation and management of an established patient, which requires a high level of medical decision making and 40-54 minutes of total time spent on the date of the encounter
Used when metastatic disease is progressing, requiring significant changes in treatment or end-of-life discussions.
32408 - Core needle biopsy, lung or mediastinum, percutaneous, including image guidance
The standard procedure for obtaining tissue to confirm the diagnosis of secondary malignancy.
71250 - Computed tomography, thorax; without contrast material
Primary imaging modality used for detecting and measuring the size of pulmonary metastases.
78815 - Positron emission tomography with concurrently acquired computed tomography for attenuation correction and anatomical localization imaging; skull base to mid-thigh
Used for staging and assessing metabolic activity of metastatic lung lesions.
31622 - Bronchoscopy, rigid or flexible, including fluoroscopic guidance, when performed; diagnostic, with cell washing, when performed
Used to evaluate central lesions or obtain washings for cytology in suspected metastasis.
32555 - Thoracentesis, needle or catheter, aspiration of the pleural space; with imaging guidance
Performed when secondary lung neoplasms cause malignant pleural effusions.
96413 - Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug
The primary therapeutic intervention for systemic control of secondary lung neoplasms.
99205 - Office or other outpatient visit for the evaluation and management of a new patient, which requires a high level of medical decision making and 60-74 minutes of total time spent on the date of the encounter
Required for the initial consultation of a patient newly diagnosed with metastatic lung disease.
99213 - Office or other outpatient visit for the evaluation and management of an established patient, which requires a low level of medical decision making and 20-29 minutes of total time spent on the date of the encounter
Appropriate for routine follow-ups in stable patients undergoing maintenance therapy or surveillance.